Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants

Mostrar outras versões (1)

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, Mcshane, H
Formato:	Journal article
Idioma:	English
Publicado em:	2011

Registros relacionados

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
por: Ota, M, et al.
Publicado em: (2011)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
por: Odutola, A, et al.
Publicado em: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
por: Odutola, A, et al.
Publicado em: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Brookes, R, et al.
Publicado em: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Roger H Brookes, et al.
Publicado em: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
por: Roger H. Brookes, et al.
Publicado em: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
por: Rowland, R, et al.
Publicado em: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
por: Pathan, A, et al.
Publicado em: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, A, et al.
Publicado em: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
por: Owiafe, P, et al.
Publicado em: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
por: Ibanga, H, et al.
Publicado em: (2006)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
por: Whelan, K, et al.
Publicado em: (2009)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
por: Imoukhuede, E, et al.
Publicado em: (2006)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
por: Harris, S, et al.
Publicado em: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
por: Sander, C, et al.
Publicado em: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
por: Meyer, J, et al.
Publicado em: (2013)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
por: Mensah, V, et al.
Publicado em: (2017)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado em: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
por: Hawkridge, T, et al.
Publicado em: (2008)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
por: Kathryn T. Whelan, et al.
Publicado em: (2011-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
por: Rowland, R, et al.
Publicado em: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
por: Mcshane, H
Publicado em: (2008)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
por: White, A, et al.
Publicado em: (2013)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
por: Scriba, T, et al.
Publicado em: (2011)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
por: Mcshane, H, et al.
Publicado em: (2005)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Publicado em: (2011-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: Mcshane, H, et al.
Publicado em: (2016)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, A, et al.
Publicado em: (2011)

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
por: Mullarkey, C, et al.
Publicado em: (2013)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
por: Dieye, T, et al.
Publicado em: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
por: Thomas, Z, et al.
Publicado em: (2014)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
por: de Cassan, S, et al.
Publicado em: (2010)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
por: Fletcher, H, et al.
Publicado em: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
por: Satti, I, et al.
Publicado em: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
por: Satti, I, et al.
Publicado em: (2014)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, A, et al.
Publicado em: (2017)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
por: Ota, M, et al.
Publicado em: (2007)

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
por: Antrobus, R, et al.
Publicado em: (2014)

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
por: Antrobus, R, et al.
Publicado em: (2014)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
por: Anne Wajja, et al.
Publicado em: (2017-05-01)